Evolent Health News

Aktie
WKN:  A14UCN ISIN:  US30050B1017 US-Symbol:  EVH Branche:  Gesundheitswesen: Anbieter u. Dienstleister Land:  USA
1,95 €
+0,02 €
+1,04%
02.04.26
Depot/Watchlist
Marktkapitalisierung *
411,27 Mio. €
Streubesitz
-
KGV
63,69
Index-Zuordnung
-

Evolent Health News

19.03.26 - PR Newswire
Evolent announces appointment of Archie Mayani as chief product officer
Evolent announces appointment of Archie Mayani as chief product officer PR Newswire
26.02.26 - PR Newswire
Evolent to Participate in Upcoming Investor Conferences
Evolent to Participate in Upcoming Investor Conferences PR Newswire
24.02.26 - PR Newswire
Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results
Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results PR Newswire
04.02.26 - PR Newswire
Evolent To Release 2025 Fourth Quarter and Year-End Financial Results on Tuesday, February 24, 2026
Evolent To Release 2025 Fourth Quarter and Year-End Financial Results on Tuesday, February 24, 2026 PR Newswire
02.01.26 - PR Newswire
Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08
Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08 PR Newswire
06.11.25 - PR Newswire
Evolent and American Oncology Network unveil innovative model seeking to improve cancer care while eliminating prior authorization burden
Evolent and American Oncology Network unveil innovative model seeking to improve cancer care while eliminating prior authorization burden PR Newswire
06.11.25 - PR Newswire
Evolent Announces Third Quarter 2025 Results
Evolent Announces Third Quarter 2025 Results PR Newswire
09.10.25 - PR Newswire
Evolent To Release Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Evolent To Release Third Quarter 2025 Financial Results on Thursday, November 6, 2025 PR Newswire
23.09.25 - PR Newswire
Evolent Announces Strategic Divestiture of its Value-Based Primary Care Business, Evolent Care Partners
Evolent Announces Strategic Divestiture of its Value-​Based Primary Care Business, Evolent Care Partners PR Newswire
19.08.25 - PR Newswire
Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock
Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common ...
18.08.25 - PR Newswire
Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock
Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock PR Newswire
07.08.25 - PR Newswire
Evolent Announces Second Quarter 2025 Results
Evolent Announces Second Quarter 2025 Results PR Newswire
29.07.25 - PR Newswire
NYSE Content Advisory: Pre-market update + Wall Street anticipates Fed's next move
NYSE Content Advisory: Pre-​market update + Wall Street anticipates Fed's next move PR Newswire
29.07.25 - PR Newswire
NYSE Content Advisory: Pre-market update + Wall Street anticipates Fed's next move
NYSE Content Advisory: Pre-​market update + Wall Street anticipates Fed's next move PR Newswire
14.07.25 - PR Newswire
Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025 PR Newswire
09.07.25 - PR Newswire
Evolent announces key appointments to leadership team
Evolent announces key appointments to leadership team PR Newswire
20.06.25 - PR Newswire
Evolent reiterates Q2 and full year guidance for Adjusted EBITDA
Evolent reiterates Q2 and full year guidance for Adjusted EBITDA PR Newswire
08.05.25 - PR Newswire
Evolent Announces First Quarter 2025 Results
Evolent Announces First Quarter 2025 Results PR Newswire
22.04.25 - PR Newswire
Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors
Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors PR Newswire
15.04.25 - PR Newswire
Evolent program achieves 20% reduction in use of low-value oncology regimens
Evolent program achieves 20% reduction in use of low-value oncology regimens PR Newswire

Newssuche

Videos

newspaper
01.04.26
Saisonalitäten: DAS machst Du falsch!
Viele Trader landen irgendwann bei Saisonalitäten, ziehen diesen stark fundamental basierten Ansatz ... Mehr »